The efficacy comparison between glargine and biphasic insulin aspart 30(BIAsp 30) after CSII in newly diagnosed type 2 diabetes mellitus
10.3969/j.issn.1006-6187.2009.12.009
- VernacularTitle:甘精胰岛素与双相门冬胰岛素用于初诊2型糖尿病患者胰岛素泵治疗后的疗效比较
- Author:
Yadong SUN
;
Yan MA
;
Le YANG
- Publication Type:Journal Article
- Keywords:
Insulin;
Newly diagnosed type 2 diabetes mellitus;
Continuous subcutaneous insulin infusion;
Blood glucose;
Hemoglobin A1C
- From:
Chinese Journal of Diabetes
2009;17(12):908-910
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and safety of glargine(Lantus) versus biphasic insulin aspart 30 (30% free and 70% protamine-bound, BIAsp 30) after continuous subcutaneous insulin infusion treatment (CSII) in newly diagnosed type 2 diabetes mellitus. Methods A 20 week open and random study was performed. All 60 patients with newly diagnosed T2DM were randomly divided into two groups. Group B patients was treated by glargine and group A received treatment with BIAsp 30 administered immediately before dinner and breakfast. Blood glucose at 7 time points, glycosylated hemoglobin A1c(HbA1c) and hypoglycemia were observed. Results The postprandial glucose(PPG) was significantly lower in group B than in group A (P<0.05), and the frequency of hypoglycaemic episodes was lower in group B than in group A (P<0.05). The fasting blood glucose(FBG) was not different between two groups (P>0.05). And there was no difference between two groups in HbA1c and other adverse events. Conclusions Glargine is surperior to BIAsp30, not only in controlling the PPG but also in reducing the incidence of hypoglycemia.
